Over the next few years, after being heavily promoted to physicians and the general public, Vioxx and Celebrex became widely used by millions of persons who had little risk of GI bleeding.

Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...